Abstract 156P
Background
The aim of this study was to understand the impact of the COVID-19 pandemic on the treatment patterns for patients with stage III unresectable non-small cell lung cancer (uNSCLC).
Methods
This was a retrospective chart review study of stage III uNSCLC patients diagnosed between 1 October 2017 and 31 May 2021 in France, Germany, Italy, Spain, Canada, and the USA.
Results
Of 351 enrolled patients (median age 70 years [range 44-91]; 63.5% male), 88 and 263 were treated prior to (Cohort 1) and during (Cohort 2) the pandemic, respectively. The majority in Cohort 1 (89.8%) and Cohort 2 (82.5%) received platinum-based chemoradiotherapy (CRT). Among patients receiving CRT, the proportion who received sequential CRT (sCRT) was higher in Cohort 2 compared to Cohort 1 (20.3% vs 12.7%). Median treatment durations of completed concurrent CRT and sCRT were 64.0 and 145.5 days, respectively, in all patients and similar between cohorts. A higher proportion received consolidation durvalumab in Cohort 2 compared to Cohort 1 (67.3% vs 40.5%). Compared to Cohort 1, Cohort 2 had a lower median time to durvalumab initiation (41.0 vs 51.5 days since CRT end) and a longer median duration of durvalumab treatment (336.0 vs 147.5 days). Among all patients, a higher proportion of Cohort 2 experienced dose/schedule modifications compared to Cohort 1 (28.1% vs 14.8%). The proportion of patients experiencing any adverse events (AEs) of interest was similar between Cohort 1 (67.0%) and Cohort 2 (67.3%). Of AEs collected, lower proportions were reported in Cohort 2 vs Cohort 1 for pneumonitis (7.8% vs 14.9%) and interstitial lung disease (0% vs 3.2%).
Conclusions
In this study, stage III uNSCLC patients continued to receive the SOC during the pandemic (Cohort 2), with a higher proportion receiving durvalumab, a shorter time to durvalumab initiation, and a longer durvalumab treatment duration compared to prior to the pandemic (Cohort 1). Higher proportions of patients in Cohort 2 compared to Cohort 1 received sCRT and had dose/schedule modifications to potentially help mitigate toxicities and alleviate healthcare system burden. SOC was maintained during the pandemic, indicating a strong attention to patient care and increased awareness of the PACIFIC regimen.
Clinical trial identification
D4191C00119.
Editorial acknowledgement
Editorial support with the development of this abstract, under the direction of the authors, was provided by Steve Hill, PhD, of Ashfield MedComms, an Inizio company, and was funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
P. Borghetti: Financial Interests, Personal, Invited Speaker: AstraZeneca-Roche; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, Roche, MSD. K. Hsieh: Other, Personal and Institutional, Research Grant: AstraZeneca. L. Cai: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. P. Chander: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca; Financial Interests, Institutional, Stocks/Shares: AstraZeneca. Y. Qiao: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca; Financial Interests, Institutional, Stocks/Shares: AstraZeneca. N. Frost: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, BeiGene, Berlinchemie, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Merck Sharp&Dohme, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda; Financial Interests, Personal and Institutional, Research Grant: Roche; Non-Financial Interests, Personal, Member: German Respiratory Society (Deutsche Gesellschaft für Pneumologie), German Cancer Society (Deutsche Krebsgesellschaft), ESMO, IASLC, European Respiratory Society (ERS); Non-Financial Interests, Personal, Leadership Role: German Respiratory Society (Deutsche Gesellschaft für Pneumologie), German Cancer Society (Deutsche Krebsgesellschaft; working group medical oncology). All other authors have declared no conflicts of interest.